Ferrosan Asia Pacific Pte Ltd (FAP), which markets healthcare product brands like Imedeen and Zinaxin Plus in eight countries in the region, expects sales in Malaysia to account for 30% of its regional revenue next year.
“Sales of our products in Malaysia are expected to grow over 20% annually, backed by new product launches and increased marketing efforts,'' FAP managing director Jan G. Vistisen said.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!